Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-25-003609
Filing Date
2025-08-14
Accepted
2025-08-14 15:57:11
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9037
  Complete submission text file 0000902664-25-003609.txt   10712
Mailing Address 632 BROADWAY SUITE 602 NEW YORK NY 10012
Business Address 632 BROADWAY SUITE 602 NEW YORK NY 10012 6469894000
Vestal Point Capital, LP (Filed by) CIK: 0001974915 (see all company filings)

EIN.: 922296021 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116
Business Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116 617-468-4219
Bicara Therapeutics Inc. (Subject) CIK: 0002023658 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94620 | Film No.: 251218244
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)